Randomized trial demonstrates platelet phagocytosis induced by IgG3 in fetal alloimmune thrombocytopenia, suggesting its role as a measurable biomarker.
Key Points
The primary aim is to investigate the role of IgG3 subclass antibodies in inducing platelet phagocytosis in fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Production of recombinant monoclonal antibodies targeting human platelet antigen-1a (HPA-1a) subclasses.
Platelet phagocytosis rates measured by whole platelet phagocytosis assay (WHOPPA) using opsonized platelets from various donors.
Flow cytometry used for validation of IgG subclass specificity and evaluation of platelet aggregate formation.
IgG3 subclass showed the highest platelet phagocytosis rates compared to IgG1, IgG2, and IgG4, demonstrating 10 times more efficiency than IgG1.
Correlation found between anti-HPA-1a antibody levels and platelet phagocytosis rates, indicating potential as a prognostic tool.
Study revealed variations in phagocytic activity based on Fc receptor interactions, highlighting the significance of IgG3 in FNAIT severity.